Ferré P, Azzout-Marniche D, Foufelle F
INSERM Unit 465, Centre de Recherches Biomédicales des Cordeliers, 15, rue de l'Ecole de Médecine, 75270 Paris Cedex 06, France.
Biochem Soc Trans. 2003 Feb;31(Pt 1):220-3. doi: 10.1042/bst0310220.
Mammalian AMP-activated protein kinase presents strong structural and functional similarities with the yeast sucrose non-fermenting 1 (Snf1) kinase involved in the derepression of glucose-repressed genes. It is now clearly established that AMP-activated protein kinase in the liver decreases glycolytic/lipogenic gene expression as well as genes involved in hepatic glucose production. This is achieved through a decreased transcriptional efficiency of transcription factors such as sterol-regulatory-element-binding protein-1c, carbohydrate-response-element-binding protein, hepatocyte nuclear factor 4 alpha or forkhead-related protein. Clearly, the long-term consequences of AMP-activated protein kinase activation have to be taken into account if activators of this enzyme are to be designed as anti-diabetic drugs.
哺乳动物的AMP激活蛋白激酶与参与解除葡萄糖抑制基因阻遏的酵母蔗糖非发酵1(Snf1)激酶在结构和功能上有很强的相似性。现已明确证实,肝脏中的AMP激活蛋白激酶会降低糖酵解/脂肪生成基因的表达以及参与肝脏葡萄糖生成的基因的表达。这是通过降低转录因子(如固醇调节元件结合蛋白-1c、碳水化合物反应元件结合蛋白、肝细胞核因子4α或叉头相关蛋白)的转录效率来实现的。显然,如果要将这种酶的激活剂设计成抗糖尿病药物,就必须考虑AMP激活蛋白激酶激活的长期后果。